$715 Million is the total value of Casdin Capital, LLC's 35 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 70.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FMI | Buy | FOUNDATION MEDICINE INC | $93,640,000 | +128.7% | 685,000 | +31.7% | 13.10% | +81.8% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $40,310,000 | +26.3% | 635,000 | +82.5% | 5.64% | +0.5% |
| MYOK | Buy | MYOKARDIA INC | $38,727,000 | +41.7% | 780,000 | +39.3% | 5.42% | +12.7% |
| BLUE | Buy | BLUEBIRD BIO INC | $31,390,000 | +26.8% | 200,000 | +37.9% | 4.39% | +0.8% |
| MGTA | New | MAGENTA THERAPEUTICS INC | $27,484,000 | – | 2,035,818 | +100.0% | 3.84% | – |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $26,592,000 | -10.7% | 270,000 | +8.0% | 3.72% | -29.0% |
| CRSP | Buy | CRISPR THERAPEUTICS AGnamen akt | $12,927,000 | +109.5% | 220,000 | +63.0% | 1.81% | +66.6% |
| BLFS | New | BIOLIFE SOLUTIONS INC | $11,410,000 | – | 1,000,000 | +100.0% | 1.60% | – |
| OSUR | Buy | ORASURE TECHNOLOGIES INC | $10,541,000 | +160.0% | 640,000 | +166.7% | 1.47% | +106.7% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $10,003,000 | +6.7% | 220,000 | +23.9% | 1.40% | -15.1% |
| EDIT | Buy | EDITAS MEDICINE INC | $6,390,000 | +44.6% | 178,333 | +33.8% | 0.89% | +15.1% |
| NTGN | New | NEON THERAPEUTICS INC | $4,263,000 | – | 338,345 | +100.0% | 0.60% | – |
| LOXO | New | LOXO ONCOLOGY INCput | $3,470,000 | – | 20,000 | +100.0% | 0.48% | – |
| CDNA | New | CAREDX INC | $2,448,000 | – | 200,000 | +100.0% | 0.34% | – |
| FIXX | Buy | HOMOLOGY MEDICINES INC | $2,346,000 | +109.1% | 115,000 | +91.7% | 0.33% | +66.5% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INput | $2,260,000 | – | 50,000 | +100.0% | 0.32% | – |
| BPMC | New | BLUEPRINT MEDICINES CORPcall | $635,000 | – | 10,000 | +100.0% | 0.09% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2018-08-20
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.